Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18419411 | METHODS FOR CHARACTERIZING CELL-FREE NUCLEIC ACID FRAGMENTS | January 2024 | October 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18530860 | METHODS OF DETECTING A LEAK FROM A SUBARRAY OF A MICROARRAY CHIP, KITS OF COMPONENTS THAT FACILITATE LEAK DETECTION, AND MICROARRAY CHIPS CONFIGURED FOR LEAK DETECTION | December 2023 | September 2024 | Allow | 9 | 2 | 1 | Yes | No |
| 18459068 | Compositions and Methods for Analyte Detection | August 2023 | March 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18454312 | Method to Use Gene Expression to Determine Likelihood of Clinical Outcome of Renal Cancer | August 2023 | May 2025 | Allow | 21 | 1 | 1 | No | No |
| 18452778 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR PARKINSON'S DISEASE PROGNOSIS | August 2023 | May 2025 | Allow | 21 | 1 | 0 | No | No |
| 18327614 | DETECTING OVARIAN CANCER | June 2023 | June 2025 | Allow | 25 | 2 | 1 | No | No |
| 18112696 | NEEDLE-BASED DEVICES AND METHODS FOR IN VIVO DIAGNOSTICS OF DISEASE CONDITIONS | February 2023 | January 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18163128 | METHODS AND SYSTEMS FOR HIGH-DEPTH SEQUENCING OF METHYLATED NUCLEIC ACID | February 2023 | June 2025 | Allow | 29 | 5 | 1 | Yes | No |
| 17962752 | Method and Device for Encapsulating Cell in Liquid Droplet for Single-Cell Analysis | October 2022 | December 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17955426 | POLYMORPHISM DETECTION WITH INCREASED ACCURACY | September 2022 | December 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17820925 | Clear Cell Renal Cell Carcinoma Biomarkers | August 2022 | August 2024 | Allow | 24 | 1 | 0 | Yes | No |
| 17813965 | ASSAY METHODS | July 2022 | May 2025 | Allow | 34 | 2 | 1 | No | No |
| 17781083 | SYSTEM AND METHOD FOR IDENTIFYING ANALYTES IN ASSAY USING NORMALIZED TM VALUES | May 2022 | May 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17711769 | ASSAY SYSTEMS FOR GENETIC ANALYSIS | April 2022 | March 2025 | Allow | 35 | 2 | 0 | Yes | Yes |
| 17585814 | METHODS AND KITS FOR DETECTION OF METHYLATION STATUS | January 2022 | June 2025 | Abandon | 41 | 5 | 0 | Yes | No |
| 17625500 | BISULFITE-FREE, WHOLE GENOME METHYLATION ANALYSIS | January 2022 | May 2025 | Allow | 40 | 2 | 0 | No | No |
| 17561562 | DETECTION OF TARGET NUCLEIC ACIDS USING HYBRIDIZATION | December 2021 | August 2024 | Allow | 32 | 1 | 0 | No | No |
| 17553182 | METHOD FOR RELATIVE QUANTIFICATION OF NUCLEIC ACID SEQUENCE, EXPRESSION, OR COPY CHANGES, USING COMBINED NUCLEASE, LIGATION, AND POLYMERASE REACTIONS | December 2021 | August 2024 | Allow | 32 | 1 | 1 | No | No |
| 17536306 | GENETIC MARKERS FOR ENHANCING EFFICACY OF ANTIPSYCHOTIC TREATMENT WITH ILOPERIDONE | November 2021 | August 2024 | Allow | 32 | 2 | 0 | No | No |
| 17521205 | COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF A GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASM | November 2021 | November 2024 | Allow | 36 | 1 | 1 | No | No |
| 17487804 | METHODS OF SEQUENCING NUCLEIC ACID MOLECULES | September 2021 | May 2025 | Abandon | 43 | 7 | 0 | Yes | No |
| 17448958 | METHOD FOR HIGHLY SENSITIVE DNA METHYLATION ANALYSIS | September 2021 | August 2024 | Allow | 35 | 2 | 0 | No | No |
| 17441207 | SERIAL BIOMARKER MEASUREMENT USING A COMPARATOR APPROACH | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17428219 | DARC EXPRESSION AS PROGNOSTICATOR OF IMMUNOTHERAPY OUTCOMES | August 2021 | April 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17292748 | GENE SIGNATURES FOR THE PREDICTION OF PROSTATE CANCER RECURRENCE | May 2021 | November 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17198932 | GENOTYPING BY POLYMERASE BINDING | March 2021 | October 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17273014 | RECURRENCE GENE SIGNATURE ACROSS MULTIPLE CANCER TYPES | March 2021 | June 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17131287 | PANCREATIC DUCTAL ADENOCARCINOMA EVALUATION USING CELL-FREE DNA HYDROXYMETHYLATION PROFILE | December 2020 | January 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17255316 | POLYNUCLEOTIDE DUPLEX PROBE MOLECULE | December 2020 | July 2025 | Abandon | 54 | 3 | 1 | No | No |
| 17109493 | PROBE, PROBE SET, AND METHOD FOR IDENTIFYING DESIRED DNA SEQUENCE IN SOLUTION | December 2020 | May 2025 | Allow | 53 | 5 | 1 | Yes | No |
| 17025822 | METHODS AND SYSTEMS FOR T CELL RECEPTOR ANALYSIS | September 2020 | December 2024 | Abandon | 51 | 4 | 1 | Yes | No |
| 16966354 | SAMPLE PREP FOR DNA LINKAGE RECOVERY | July 2020 | May 2025 | Allow | 57 | 5 | 0 | Yes | No |
| 15733113 | CHEMICAL PROBE-DEPENDENT EVALUATION OF PROTEIN ACTIVITY AND USES THEREOF | May 2020 | December 2024 | Allow | 55 | 2 | 1 | No | No |
| 16763553 | BIOMARKER PROXY TESTS AND METHODS FOR STANDARD BLOOD CHEMISTRY TESTS | May 2020 | March 2025 | Abandon | 58 | 6 | 1 | Yes | No |
| 16322462 | SEQUENTIAL PROBING OF MOLECULAR TARGETS BASED ON PSEUDO-COLOR BARCODES WITH EMBEDDED ERROR CORRECTION MECHANISM | January 2019 | May 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16194612 | METHOD AND KIT FOR TARGET MOLECULE DETECTION | November 2018 | January 2025 | Abandon | 60 | 6 | 0 | Yes | Yes |
| 16005228 | MATERIALS AND METHODS FOR ASSESSING PROGRESSION OF PROSTATE CANCER | June 2018 | November 2019 | Allow | 17 | 1 | 0 | No | No |
| 15775015 | METHODS OF DETECTING 5-HYDROXYMETHYLCYTOSINE AND DIAGNOSING OF CANCER | May 2018 | February 2025 | Abandon | 60 | 7 | 1 | Yes | Yes |
| 15967395 | MICROARRAYS | April 2018 | April 2025 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 15741344 | DROPLET SEQUENCING DEVICE | January 2018 | October 2019 | Allow | 21 | 1 | 1 | No | No |
| 15531397 | MULTIPLEX BEAD ARRAY ASSAY | May 2017 | August 2019 | Allow | 27 | 1 | 1 | Yes | No |
| 15515185 | USE OF HLA GENETIC STATUS TO ASSESS OR SELECT TREATMENT OF CELIAC DISEASE | March 2017 | March 2019 | Allow | 24 | 1 | 1 | No | No |
| 15443499 | MATERIALS AND METHODS FOR DIAGNOSIS, PROGNOSIS AND ASSESSMENT OF THERAPEUTIC/PROPHYLACTIC TREATMENT OF PROSTATE CANCER | February 2017 | January 2019 | Allow | 23 | 1 | 1 | Yes | No |
| 15437147 | METHODS FOR IDENTIFYING SUBJECTS WITH A GENETIC RISK FOR DEVELOPING IGA NEPHROPATHY | February 2017 | March 2019 | Allow | 25 | 1 | 1 | Yes | No |
| 15315482 | NUCLEOTIDE POLYMORPHISM DETECTION METHOD | December 2016 | December 2018 | Allow | 24 | 1 | 0 | Yes | No |
| 15273205 | METHODS FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA AND THE USE OF BIOMARKERS AS A PREDICTOR OF RESPONSIVENESS TO DRUGS | September 2016 | February 2020 | Allow | 41 | 3 | 1 | Yes | No |
| 15272283 | CANCER TREATMENT WITH C-MET ANTAGONISTS AND CORRELATION OF THE LATTER WITH HGF EXPRESSION | September 2016 | October 2018 | Allow | 25 | 1 | 1 | No | No |
| 15221154 | METHOD AND COMPOSITIONS FOR DETECTING EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT FORMS IN CANCER CELLS | July 2016 | November 2018 | Allow | 28 | 2 | 1 | Yes | No |
| 15032325 | NUCLEIC ACIDS AND METHODS FOR DETECTING PATHOGENS AND BENEFICIAL MICROORGANISMS | April 2016 | June 2019 | Allow | 49 | 4 | 0 | Yes | No |
| 14938240 | HYBRIDIZATION PROBES AND METHODS | November 2015 | March 2018 | Allow | 28 | 2 | 1 | Yes | No |
| 14890424 | DNA Methylation Biomarkers for Bladder Cancer | November 2015 | October 2019 | Allow | 47 | 3 | 1 | Yes | No |
| 14788195 | MATERIALS AND METHODS FOR ASSESSING PROGRESSION OF PROSTATE CANCER | June 2015 | January 2018 | Allow | 30 | 3 | 1 | Yes | No |
| 14294011 | DETECTION OF NUCLEIC ACIDS USING UNMODIFIED GOLD NANOPARTICLES | June 2014 | September 2017 | Allow | 40 | 2 | 0 | Yes | Yes |
| 13981601 | Colon Cancer Gene Expression Signatures and Methods of Use | October 2013 | September 2018 | Allow | 60 | 4 | 1 | Yes | Yes |
| 13823730 | CAPTURE BASED NUCLEIC ACID DETECTION | May 2013 | January 2016 | Allow | 34 | 1 | 1 | No | No |
| 13728912 | METHOD AND COMPOSITIONS FOR DETECTING EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT FORMS IN CANCER CELLS | December 2012 | March 2016 | Allow | 39 | 2 | 1 | Yes | No |
| 13724527 | MICROORGANISM NUCLEIC ACID PURIFICATION FROM HOST SAMPLES | December 2012 | August 2017 | Allow | 56 | 6 | 0 | No | No |
| 13721081 | MATERIALS AND METHODS FOR DIAGNOSIS, PROGNOSIS AND ASSESSMENT OF THERAPEUTIC/PROPHYLACTIC TREATMENT OF PROSTATE CANCER | December 2012 | November 2016 | Allow | 47 | 3 | 1 | Yes | No |
| 13502518 | METHODS AND SYSTEMS FOR PHARMACOGENOMIC TREATMENT OF CARDIOVASCULAR CONDITIONS | September 2012 | June 2016 | Allow | 50 | 4 | 2 | Yes | No |
| 12864641 | METHOD AND DEVICE FOR THE AUTOMATED PROCESSING OF A SAMPLE | December 2011 | November 2014 | Allow | 52 | 3 | 0 | Yes | No |
| 13259350 | Bioagent Detection Systems, Devices, And Methods | November 2011 | June 2016 | Allow | 56 | 5 | 0 | Yes | No |
| 13187190 | BIOLAYER INTERFEROMETRY MEASUREMENT OF BIOLOGICAL TARGETS | July 2011 | July 2013 | Allow | 23 | 1 | 1 | Yes | No |
| 13173247 | ULTRA HIGH-THROUGHPUT OPTI-NANOPORE DNA READOUT PLATFORM | June 2011 | January 2014 | Allow | 30 | 3 | 0 | Yes | No |
| 13152260 | Methods and Systems for Sequential Determination of Genetic Mutations and/or Varients | June 2011 | July 2017 | Allow | 60 | 6 | 0 | No | No |
| 13062247 | METHOD FOR DETECTION OF CANCER BASED ON SPATIAL GENOME ORGANIZATION | March 2011 | November 2016 | Allow | 60 | 5 | 1 | Yes | Yes |
| 13015915 | METHODS AND COMPOSITIONS FOR SEQUENCE-SPECIFIC PURIFICATION AND MULTIPLEX ANALYSIS OF NUCLEIC ACIDS | January 2011 | February 2017 | Allow | 60 | 7 | 1 | Yes | No |
| 12996457 | DETECTION PROBE | December 2010 | November 2013 | Allow | 36 | 4 | 1 | Yes | No |
| 12956525 | POLYMORPHISMS ASSOCIATED WITH PARKINSON'S DISEASE | November 2010 | January 2012 | Allow | 14 | 0 | 1 | Yes | No |
| 12812215 | MALIGNANCY-RISK SIGNATURE FROM HISTOLOGICALLY NORMAL BREAST TISSUE | October 2010 | April 2015 | Allow | 57 | 4 | 1 | Yes | No |
| 12914055 | METHOD FOR TESTING MICROORGANISM OR THE LIKE AND TESTING APPARATUS THEREFOR | October 2010 | August 2014 | Allow | 45 | 3 | 1 | Yes | No |
| 12867680 | SUSCEPTIBILITY VARIANTS FOR LUNG CANCER | August 2010 | March 2014 | Allow | 43 | 4 | 1 | Yes | No |
| 12843517 | RNA-BASED SYSTEM AND METHOD TO DIFFERENTIATE SEAFOOD | July 2010 | October 2013 | Allow | 39 | 4 | 1 | Yes | No |
| 11920978 | System for the Integrated and Automated Analysis of DNA or Protein and Method for Operating Said Type of System | July 2009 | March 2015 | Allow | 60 | 7 | 1 | Yes | No |
| 11915645 | GENE METHYLATION AND EXPRESSION | June 2008 | September 2016 | Allow | 60 | 8 | 1 | Yes | Yes |
| 12002579 | METHOD OF PREPARING A BIOLOGICAL SPECIMEN SLIDE | December 2007 | January 2013 | Allow | 60 | 4 | 0 | No | No |
| 11786260 | Differential multiplexing with pattern recognition | April 2007 | February 2013 | Allow | 60 | 3 | 1 | Yes | No |
| 11365556 | Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins | February 2006 | March 2016 | Allow | 60 | 6 | 2 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DAUNER, JOSEPH G.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DAUNER, JOSEPH G works in Art Unit 1682 and has examined 76 patent applications in our dataset. With an allowance rate of 80.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 41 months.
Examiner DAUNER, JOSEPH G's allowance rate of 80.3% places them in the 43% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by DAUNER, JOSEPH G receive 2.91 office actions before reaching final disposition. This places the examiner in the 94% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by DAUNER, JOSEPH G is 41 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +15.3% benefit to allowance rate for applications examined by DAUNER, JOSEPH G. This interview benefit is in the 59% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 18.5% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 42.5% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 70.6% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.